文献速递前列腺癌

恩杂鲁胺治疗转移性激素敏感性前列腺癌:ARON-3国际多中心真实世界研究结果

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2026-01-08

ARON-3研究回顾性纳入9国29个中心的424例接受恩杂鲁胺治疗的转移性激素敏感性前列腺癌患者,中位治疗时间31.8个月,中位总生存未达到;76%患者PSA90、59%患者PSA0.2,仅淋巴结转移模式及PSA深度应答与更长的治疗时间和更好的总生存相关,≥3级不良事件发生率9%-10%。

要点

  • 恩杂鲁胺在mHSPC真实世界中显示持久疗效,中位治疗时间31.8个月,中位OS未达到。
  • 76%患者达到PSA90,59%达到PSA0.2,中位至PSA90和PSA0.2分别为6.0和8.3个月。
  • 仅淋巴结转移模式与PSA90及超低PSA应答均与更长治疗时间和更好OS显著相关。

核心结论

  • 真实世界临床实践证实恩杂鲁胺在mHSPC患者中有效且安全,与临床试验结果一致。

研究设计与样本

  • ARON-3为国际多中心回顾性研究,从9国29个癌症中心病历提取数据,纳入424例接受恩杂鲁胺治疗的mHSPC患者。
  • 采用Kaplan-Meier法估计总生存(OS)和治疗持续时间(ToT),PSA90定义为较基线PSA下降≥90%,PSA0.2定义为PSA≤0.2 ng/ml。
  • 不良事件按CTCAE v5.0分级。

主要发现

  • 424例患者中80例(19%)仅淋巴结转移、265例(63%)仅骨转移、50例(12%)内脏转移;273例(64%)为同时性转移,151例(36%)为异时性转移。
  • 228例诊断为低瘤负荷,196例(46%)为高瘤负荷。
  • 中位ToT为31.8个月,中位OS未达到。
  • 76%患者达到PSA90,59%达到PSA0.2,中位至PSA90和PSA0.2分别为6.0个月和8.3个月。
  • 仅淋巴结转移模式、PSA90和超低PSA应答与更长治疗时间和更好OS显著相关;≥3级不良事件在<70岁和≥70岁患者中分别为9%和10%。

临床怎么用

  • 恩杂鲁胺可作为mHSPC的真实世界治疗选择,疗效与临床试验一致。
  • 治疗中应关注PSA深度应答(PSA90和PSA0.2)及转移模式,仅淋巴结转移者可能获益更持久。
  • ≥70岁患者≥3级不良事件发生率与<70岁患者相近(10% vs 9%),安全性可接受。

局限性

  • 回顾性研究设计,数据来自病历提取,可能存在选择偏倚和信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enzalutamide (ENZA), a next-generation non-steroidal androgen receptor (AR) inhibitor, plays a pivotal role in the management of both hormone-sensitive (HSPC) and androgen deprivation-resistant prostate cancer (ARPC). This paper presents real-world clinical outcomes of ENZA in a subgroup of metastatic HSPC (mHSPC) patients included in the ARON-3 study. METHODS: Clinical information was extracted retrospectively from medical records at 29 cancer centres in 9 countries worldwide. Overall Survival (OS) was calculated from starting ENZA to death from any cause and the time on treatment (ToT) from ENZA initiation to discontinuation for any reason. The Kaplan-Meier method was used to estimate OS and ToT. PSA90 was defined as a ≥90% PSA reduction from baseline, and PSA0.2 as the achievement of an ultra-low PSA level ≤0.2 ng/ml. Adverse events (AEs) were categorised according to Common Terminology Criteria for Adverse Events v5.0. RESULTS: The study population comprised 424 patients treated with ENZA for mHSPC, of whom 80 (19%) had lymph node-only metastases, 265 (63%) bone-only metastases, and 50 (12%) visceral metastases. 273 patients (64%) had synchronous metastases and 151 (36%) had developed metachronous metastases. A total of 228 patients were diagnosed with low-volume disease, and 196 patients (46%) with high-volume disease. The median ToT was 31.8 months, and the median OS was not reached. The median time to PSA90 (achieved in 76% of patients) and PSA0.2 (59% of patients) was 6.0 months and 8.3 months, respectively. Statistically significant associations were identified between lymph node-only patterns, PSA90 and ultra-low PSA responses, and longer treatment duration and better overall survival. Grade 3-4 AEs were observed in 9% of patients <70 years and in 10% ≥70 years. CONCLUSIONS: Real-world clinical practice corroborates the findings from clinical trials, confirming the effectiveness and safety of ENZA in mHSPC patients.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Büttner T, Rizzo M, Bernal Vaca L, et al. Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study. Prostate Cancer Prostatic Dis. 2026. PMID: 41501561. doi:10.1038/s41391-025-01067-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。